Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have heart- and kidney-related benefits for patients with and without diabetes that go beyond their initial indication for lowering blood sugar levels.
Researchers investigate the role of the mast-cell-specific receptor Mas-related G-protein-coupled receptor B2 (MrgprB2) in alcohol-withdrawal-induced headaches.